INFORMATIONAL ONLY (NO CME): Uterine Fibroids: Overview and Update on ACOG guidelines, including trial data of Myfembree (relugolix/ethinyl estradiol/NETA)
- Event Type
- Informational
- Sponsor
- Pfizer Inc.
- Date
- Jul 21, 2022 8:00 - 9:00 am
- Speaker
- Mark Juhn, D.O. and Katie Tellor, PharmD, FACC, BCPS
- Contact
- David Haney
- dhaney@uic.edu
- Phone
- 309-655-3024
- Views
- 6
PLEASE NOTE: This event is informational only and not part of the routine OB/GYN Department Grand Rounds. As such, no CME will be provided by attending.
"Uterine Fibroids: Overview and Update on ACOG guidelines, including trial data of Myfembree (relugolix/ethinyl estradiol/NETA)," will provide a brief overview of selected patient-reported outcome measures.
Objectives:
- Provide a brief overview of uterine fibroid epidemiology and demographics (Dr. Juhn).
- Provide a simplified, tabular format of ACOG 2021 guidelines for management of uterine fibroids (Dr. Juhn).
- Review the two pivotal clinical trial data of Myfembree (relugolix/ethinyl estradiol/NETA) which led to FDA approval (Dr. Juhn).
- Provide a high-level overview of selected patient reported outcomes measures (PROMs) in uterine fibroids (Dr. Tellor).
Presenters:
Mark Juhn, D.O.
Sr. Director, Field Medical Director
Women’s Health and Metabolism
Pfizer Inc.Katie Tellor, PharmD, FACC, BCPS
Director, Internal Medicine Field Medical Outcomes & Analytics
Pfizer Inc.